SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tommysdad who wrote (5767)12/15/1998 11:54:00 AM
From: Joe E.  Read Replies (2) of 6136
 
<<Several major pharmaceutical companies had programs targeting the common cold, and abandoned them due to concerns like these. Does AGPH have a shot? Anyone care to comment?>>

The discussion on this board has been that the population for which this drug is aimed is that subset of people for whom a cold can be life threatening. Emphysema sufferers and others with reduced long capacity, people with compromised immune systems, perhaps people with cystic fibrosis and the elderly.

For the general population, unless it works within 24 hours, it may not make much sense. But this is just my impression.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News